Open an account

Royalty Pharma

RPRX · NASDAQ

$62.25+$1.98 (+3.29%)TodayMarket closed ·
Prev close $60.27

About RPRX

Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 100 full-time employees. The company went IPO on 2020-06-16. The company collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.

Employees
100
Headquarters
New York City, New York
Listed
Jun 16, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
royaltypharma.com

RPRX key statistics

Market cap
34.66B
Price-earnings ratio
32.06
Dividend yield
1.15%
Average volume
3.07M
Volume
1.87M
Open price
$60.92
High today
$62.42
Low today
$60.78
52 Week high
$64.38
52 Week low
$35.87

Royalty Pharma (RPRX) at a glance

As of Oct 20, 2026, Royalty Pharma (RPRX) shares are priced at $62.25, giving the company a market cap of 34.66B, a price-to-earnings ratio of 32.06 and a dividend yield of 1.15%.

Today the stock has traded between $60.78 and $62.42. The current price is 2.4% above the day's low and 0.3% below its high.

Volume so far is 1.87M shares, below the average of 3.07M shares a day.

Over the past year Royalty Pharma has ranged from $35.87 to $64.38, and now sits 93% of the way up that range.

Royalty Pharma met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $1.32 per share against an estimate of $1.30.

The average analyst price target is $64.49, 3.6% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $64.49
Low
$46.46
Now
$62.25
High
$73.50

RPRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 5.9% on average.

  1. Q3 FY24: reported $1.01 per share against an estimate of $0.947
  2. Q4 FY24: reported $1.15 per share against an estimate of $1.08
  3. Q1 FY25: reported $0.65 per share against an estimate of $1.62
  4. Q2 FY25: reported $1.14 per share against an estimate of $1.11
  5. Q3 FY25: reported $1.17 per share against an estimate of $1.06
  6. Q4 FY25: reported $1.47 per share against an estimate of $1.35
  7. Q1 FY26: reported $1.30 per share against an estimate of $1.24
  8. Q2 FY26: reported $1.32 per share against an estimate of $1.30

RPRX news

  • Kaustubh Bagalkote

    Why Is Eli Lilly Stock Falling Tuesday?

  • Vandana Singh

    Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

  • Vandana Singh

    Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

  • Vandana Singh

    Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial

  • Vandana Singh

    Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

  • Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript

  • Press releaseGlobe Newswire

    Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

  • Vishaal Sanjay

    Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight

Similar companies

Companies in the same industry as Royalty Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.